Q-omics provides the consensus-scored IL34 profile across patient tissues and cancer cell-line models. IL34 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IL34 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, IL34 RNA expression shows 15,731 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight HNSC, and LUAD as cancer lineages where IL34 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL34 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL34 survival associations across molecular data types. IL34 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL34 RNA expression–survival associations across cancer types. High IL34 expression shows unfavorable associations in ACC and KIRC, but favorable associations in HNSC, LUAD, CESC and LUSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IL34 RNA expression.
This table summarizes IL34 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IL34. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL34 shows lower tumor expression in HNSC, BLCA, LUAD and BRCA and higher tumor expression in KIRC and LIHC. The HNSC box plot shows higher IL34 RNA expression in normal versus tumor tissue (log2 FC = −2.127, t-test p < 0.001).
This table shows molecular features associated with IL34 in patient tissues and cancer cell lines. In patient samples, IL34 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, IL34 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
